keytruda
MSD’s Keytruda boosts overall survival by 31% in advanced oesophageal cancer
January 16, 2019Research and Development Cancer, MSD, keytruda, oesophageal cancer, pharma
MSD has unveiled new Phase 3 data for its blockbuster anti-PD-1 immunotherapy Keytruda (pembrolizumab), showing that the drug succeeded in …
Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer
November 22, 2018Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma
MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …
MSD’s Keytruda to treat melanoma in England on the Cancer Drugs Fund
November 19, 2018Sales and Marketing England, MSD, NHS, UK, keytruda, melanoma, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it …
MSD’s Keytruda improvess overall survival in Phase 3 oesophageal cancer
November 15, 2018Research and Development Cancer, MSD, PD-L1, keytruda, pharma
MSD has announced new Phase 3 data on its anti-PD-1 therapy Keytruda (pembrolizumab) as a second-line treatment for advanced or …
MSD’s Keytruda chalks up FDA approval in liver cancer
November 12, 2018Sales and Marketing Cancer, FDA, US, hepatocellular carcinoma, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda has secured another FDA approval, this time for the treatment of hepatocellular carcinoma (HCC) in patients …
MSD’s Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer
November 1, 2018Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or …
First-line Keytruda shows better overall survival in head & neck cancer
October 23, 2018Manufacturing and Production, Research and Development Cancer, ESMO 2018, MSD, head and neck cancer, keytruda, pharma
MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new …
MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer
October 19, 2018Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma
MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …
MSD to launch Keytruda at half US list price in China
September 20, 2018Business Services, Sales and Marketing BMS, China, MSD, global, keytruda, markets, pricing
US pharma giant MSD will offer cutting edge cancer treatment Keytruda to Chinese patients at half the price at what …
Keytruda scores ground-breaking European approval in lung cancer subgroup
September 10, 2018Sales and Marketing Cancer, EU, Europe, MSD, Merck, NSCLC, keytruda, lung cancer, pharma
Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based …
NICE recommends MSD’s Keytruda for advanced PD-L1-positive lung cancer
June 5, 2018Research and Development MSD, Merck, NHS, NICE, keytruda, pharma
UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS …
MSD’s Keytruda scores impressive first-line lung cancer data
May 24, 2018Research and Development, Sales and Marketing MSD, biotech, drugs, keytruda, pharma, pharmaceutical
MSD Keytruda has enjoyed the most success of the PD-1/L1 therapies in clinical trials recently and it’s rapidly cementing its …
The May 2018 issue of Pharmafocus is now live!
April 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, MSD, Pharmafocus, Shire, Takeda, flypharma, keytruda, mhealth, mobile health summit, opdivo, pharma, sugar tax
Just in time for the first good weather of the year, the May 2018 edition of Pharmafocus is available to …
Top Ten most popular articles on Pharmafile.com this week
April 20, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical
It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …
Keytruda success continues, beating Opdivo in lung cancer survival
April 17, 2018Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
